Norris Medicines posted a significantly narrower net loss of ₹28.06 lakh for FY26, down from ₹123.75 lakh in the previous year. The pharmaceutical manufacturer reported revenue from operations of ₹813.20 lakh, up 39.7% year-on-year, marking a notable operational improvement despite ongoing margin pressures.

Financial Performance

The company’s total revenue reached ₹817.74 lakh, compared to ₹588.15 lakh in FY25. While the top-line growth was robust, profitability remains constrained by high fixed costs and operating expenses. The loss before tax narrowed to ₹28.06 lakh from ₹117.81 lakh previously.

What the Numbers Show

Despite the 40% revenue surge, the company recorded a net loss, indicating that cost structures are not yet optimized for the higher volume. Finance costs rose to ₹50.00 lakh from ₹43.96 lakh, while employee benefit expenses increased to ₹166.90 lakh. This divergence between revenue growth and profit retention suggests that fixed overheads and interest burdens are absorbing the incremental operating leverage.

AGM and Corporate Actions

The 35th Annual General Meeting is scheduled for September 29, 2026. Key agenda items include:

• Reappointment of Mr. Praveen J. Bafna as a director.
• Appointment of Mr. Vimal D. Shah as Managing Director for three years, with a salary cap of ₹24 lakh per annum.
• Seeking shareholder approval for borrowing up to ₹50 crore under Section 180(1)(c) of the Companies Act.
• Authorization for sale or lease of undertaking up to ₹50 crore.

Auditor Qualifications and Compliance

Statutory auditors issued a qualified opinion due to the non-provision of gratuity liability based on actuarial valuation as required by Ind AS 19. Additionally, the company has not settled matured gratuity dues payable to former employees. The auditors also highlighted going concern risks, citing negative working capital of ₹3.71 crore and inability to meet payroll obligations regularly.

The secretarial audit report noted delays in publishing financial results for three quarters and a penalty imposed by BSE for late submission of investor complaints. The company is currently in the process of updating its website disclosures and rectifying audit trail maintenance issues.

Norris Medicines Limited appointed Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective July 30, 2026. The Board of Directors approved the appointment during a meeting held on July 30, 2026, acting on recommendations from both the Audit Committee and the Nomination and Remuneration Committee. The appointment was made pursuant to Section 203 of the Companies Act, 2013 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board meeting commenced at 5:00 PM and concluded at 5:30 PM on July 30, 2026. Norris Medicines Limited submitted the disclosure to BSE Limited, citing compliance with SEBI Circular Ref. No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Appointment Details

Patel's term of appointment is subject to terms and conditions, including remuneration, to be mutually agreed upon between him and the Board of Directors. He is not related to any existing Directors or Key Managerial Personnel of the company. The filing confirms that Patel is not debarred from holding office by virtue of any SEBI Order or other authority, nor is he disqualified under Section 164 of the Companies Act, 2013.

Candidate Profile

Iqubal Ismail Patel holds a Graduate degree and has been associated with Norris Medicines Limited for more than 11 years. His experience spans finance, accounts, taxation, budgeting, financial planning, and corporate management. According to the filing, he has played a significant role in the company's financial operations and strategic initiatives in the past. His long-standing association with the organization suggests continuity in financial strategy rather than a shift in direction. With over a decade of internal experience, Patel is positioned to manage financial planning and corporate governance matters, bringing deep familiarity with the company's operational framework and regulatory history.